Japan OKs Roche's Avastin for aggressive brain cancer

Roche has obtained approval from the Japanese Ministry of Health, Labour and Welfare to market Avastin, or bevacizumab, as a treatment for malignant glioma, including newly diagnosed glioblastoma, in combination with radiotherapy and temozolomide, and as a monotherapy for recurrent GBM and certain kinds of high-grade glioma. The approval makes Avastin the first globally approved drug for newly diagnosed glioblastoma.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX